Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Combination Therapy Reduces HbA1c and Weight in Type 2 Diabetes
Última actualización 12 de septiembre de 2026
Key finding
HbA1c reductions ranged from -8.4 to -26.1 mmol/mol.
This study evaluated the effects of exenatide once weekly combined with dapagliflozin on HbA1c and body weight in adults with type 2 diabetes, finding significant reductions in both measures.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of exenatide once weekly combined with dapagliflozin on HbA1c and body weight in adults with type 2 diabetes, finding significant reductions in both measures.
Clinical relevance
These findings are significant as they suggest that combining exenatide with dapagliflozin could offer a more effective treatment strategy for managing type 2 diabetes, potentially improving patient outcomes and quality of life.
Keep in mind
Effectiveness data were unclear for some outcomes. The study did not specify the sample size. Generalizability may be limited to specific populations.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Juan PF, Elise H, Azazuddin A, et al. Exenatide Once Weekly Plus Dapagliflozin Reduces HbA1c and Body Weight in Adults with Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2018;20(6):1520-1525. doi:10.1111/dom.13296
Efectos Principales
HbA1c was reduced by -8.4 mmol/mol with exenatide once weekly plus dapagliflozin.
Body weight decreased by -2.07 kg with exenatide once weekly plus dapagliflozin.
HbA1c was reduced by -8.4 mmol/mol with exenatide once weekly.
Body weight decreased by -2.07 kg with dapagliflozin.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dapagliflozin, Exenatide, Exenatide once weekly plus dapagliflozin and Body weight, HbA1c.
This study contributes evidence to
Primary intervention
Dapagliflozin
Primary outcomes
- Body weight
- HbA1c
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
6
Evidence pairs
1122
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and HbA1c
Evidencia relacionada
Relación de evidencia
SGLT2 Inhibitors and HbA1c
Guardar evidencia
Relación de evidencia
GLP-1 Receptor Agonists and Body Weight
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- 82
- Strong
- ImpactScore™
- 79
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 9 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 3 estudios
Add to Evidence TrackerBody weight
Exenatide once weekly plus dapagliflozin → Body weight
Exenatide once weekly plus dapagliflozin → Body weight
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerHbA1c
Exenatide once weekly plus dapagliflozin → HbA1c
Exenatide once weekly plus dapagliflozin → HbA1c
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Exenatide once weekly plus dapagliflozin reduced HbA1c by -8.4 mmol/mol.
- Body weight decreased by -2.07 kg with the combination therapy.
- Dapagliflozin alone also reduced HbA1c by -8.4 mmol/mol.
A quién se aplica
- Adults diagnosed with type 2 diabetes.
- Individuals seeking additional treatment options for blood sugar control.
Tener en Cuenta
- Results may not apply to all demographics of type 2 diabetes patients.
- Further studies are needed to confirm long-term effectiveness.
- The study did not assess the impact of lifestyle changes.
Entre Líneas
- Effectiveness data were unclear for some outcomes.
- The study did not specify the sample size.
- Generalizability may be limited to specific populations.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
SGLT2 Inhibitors → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 82
- Strong
- ImpactScore™
- 79
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 9 estudios
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 3 studies
- ImpactScore™
- 83
- Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 3 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
9 studies
outcome_hubMeasures HbA1c as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
9 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Body Weight Evidence Hub
All studies measuring Body Weight
3 studies
outcome_hubMeasures Body Weight as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
3 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Dapagliflozin and HbA1c
Intervention: DapagliflozinOutcome: HbA1c
9 results
All studies on Exenatide and Body weight
Intervention: ExenatideOutcome: Body weight
3 results
All studies on Dapagliflozin
Intervention: Dapagliflozin
9 results
All studies on Exenatide
Intervention: Exenatide
3 results
All studies measuring HbA1c
Outcome: HbA1c
9 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists lower HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appear to lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 45 supporting studies with consistent results and a positive effect signal.
Do SGLT2 Inhibitors lower HbA1c?
Strong Evidence
SGLT2 Inhibitors may lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 82.5 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 27 supporting studies with consistent results and a positive effect signal.
Do GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may affect body weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 43 supporting studies with consistent results and a positive effect signal.
Do SGLT2 Inhibitors affect body weight?
Strong Evidence
SGLT2 Inhibitors may affect body weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Exenatide does not affect renal function in type 2 diabetesExenatide improves glycemic control and reduces weight in T2DM patientsDapagliflozin improves metabolic outcomes in type 2 diabetes patientsDapagliflozin may improve RAAS markers in diabetes patientsBaseline features predict exenatide efficacy in type 2 diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.